AOD-9604

Mechanism

Supports lipolysis signaling through the GH C-terminal fragment.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Fat mobilization
• Cut-phase support
• No expected hyperglycemia

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.3 (growth hormone fragments). the list

Reported adverse effects

• No expected effect on blood glucose

  Studied endpointonset: N/Areported reversible

Literature on file 6

• review or editorial
  AOD 9604 does not influence the WADA hGH isoform immunoassay (2013, cited 8x) graded on: indexed as "Letter" - secondary literature, not a study — “Letter”
• review or editorial
  Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• review or editorial
  Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025. graded on: indexed as "review-article" - secondary literature, not a study — “review-article”
• review or editorial
  Human sports drug testing by mass spectrometry. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• human case series
  Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. graded on: a case report or series — “case report”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous nothing on file either way

  A standard dose of 300 mcg per day, injected subcutaneously while fasted in the morning, is circulated as the established AOD-9604 protocol.

  The standard aod 9604 dosage is 300mcg/day injected subcutaneously, fasted, in the morning.

  On the record The corpus holds 250-500 mcg daily (raw: "250-500 mcg daily"), verified: false. No timing, fasting or morning requirement is on file.

  Source 1

• unverified community data timing common nothing on file either way

  It is circulated that injecting AOD-9604 within 1-2 hours of a meal, especially with carbohydrate, significantly reduces its efficacy.

  Injecting AOD-9604 within 1–2 hours of eating a meal, especially a carbohydrate-containing one, significantly reduces efficacy.

  On the record Nothing on file. No study of feeding state and AOD-9604 activity is in the record.

  Source 1

• unverified community data benefit common contradicts the record

  A quantified fat-loss expectation — 1-3 kg over a 12-week cycle at 300 mcg per day — is circulated as a reasonable outcome.

  1–3 kg of targeted fat loss over 12 weeks at 300mcg/day is a reasonable expectation for someone in the 20–30% body fat range.

  On the record The corpus records the human evidence as "Human research reported (unverified)", source tier "Research / Anecdotal", human evidence "Unclear". AOD-9604's development was discontinued after its Phase IIb obesity trial failed to show significant weight loss versus placebo — a fact this vendor page omits entirely while citing only the positive early trial data. The circulated benefit figure points the opposite way from the human trial outcome.

  Source 1

• unverified community data timing common nothing on file either way

  A standard cycle length of 12 weeks, with progressive results throughout, is circulated for fat-loss use.

  Standard aod 9604 cycle length is 12 weeks

  On the record The corpus dosing row holds a 12-16 week cycle range, verified: false. No human study supporting progressive results over 12 weeks is on file.

  Source 1

Identity

PubChem CID 71300630 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 71300630, the identifier on this record.

Molecular weight

1815.1

Molecular formula

C78H123N23O23S2

CAS number

221231-10-3

PubChem CID

71300630

InChI key

GVIYUKXRXPXMQM-BPXGDYAESA-N

Sequence

YLRIVQCRSVEGSCGF

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)CO)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

InChI

InChI=1S/C78H123N23O23S2/c1-9-41(8)62(101-68(115)47(18-14-28-86-78(83)84)91-69(116)50(29-38(2)3)95-63(110)45(79)30-43-19-21-44(104)22-20-43)75(122)100-61(40(6)7)74(121)94-49(23-25-56(80)105)67(114)98-55-37-126-125-36-54(65(112)88-32-57(106)89-51(76(123)124)31-42-15-11-10-12-16-42)97-70(117)52(34-102)90-58(107)33-87-64(111)48(24-26-59(108)109)93-73(120)60(39(4)5)99-71(118)53(35-103)96-66(113)46(92-72(55)119)17-13-27-85-77(81)82/h10-12,15-16,19-22,38-41,45-55,60-62,102-104H,9,13-14,17-18,23-37,79H2,1-8H3,(H2,80,105)(H,87,111)(H,88,112)(H,89,106)(H,90,107)(H,91,116)(H,92,119)(H,93,120)(H,94,121)(H,95,110)(H,96,113)(H,97,117)(H,98,114)(H,99,118)(H,100,122)(H,101,115)(H,108,109)(H,123,124)(H4,81,82,85)(H4,83,84,86)/t41-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-,62-/m0/s1

Classified as

Lipolysis Stimulationmechanism

This mechanism is the source of the most common category error on the site. A record can be well supported for lipolysis and carry nothing at all for fat loss, and the two live in different fields with different rungs on the ladder at /evidence/rubric.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• AOD-9604
• aod9604 peptide

Listed prices 244

What 159 shops we track listed for AOD-9604, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record